Basic Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Mar 15, 2023; 14(3): 209-221
Published online Mar 15, 2023. doi: 10.4239/wjd.v14.i3.209
miR-124 is upregulated in diabetic mice and inhibits proliferation and promotes apoptosis of high-glucose-induced β-cells by targeting EZH2
Xiao-Kai Duan, Yong-Xiang Sun, Hong-Yun Wang, Yan-Yan Xu, Shi-Zhen Fan, Jin-Ya Tian, Yong Yu, Yan-Yun Zhao, Yan-Li Jiang
Xiao-Kai Duan, Yong-Xiang Sun, Hong-Yun Wang, Yan-Yan Xu, Shi-Zhen Fan, Jin-Ya Tian, Yong Yu, Yan-Yun Zhao, Yan-Li Jiang, Department of General Practice, Zhengzhou First People’s Hospital, Zhengzhou 450000, Henan Province, China
Author contributions: Duan XK, Sun YX and Wang HY designed and coordinated the study; Xu YY, Fan SZ and Tian JY performed the experiments, acquired and analyzed data; Duan XK, Sun YX, YU Y, Zhao YY and Jiang YL interpreted the data and wrote the manuscript; All authors approved the final version of the article.
Supported by The Medical Science and Technology Key Project of Henan Province, No. 2018020733.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of Zhengzhou First People’s Hospital (Approval No. 202004008).
Institutional animal care and use committee statement: All animal experiments in this study were carried out in accordance with the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978). All examination procedures were meet the ethical standards formulated by institutional review board of Zhengzhou First People’s Hospital.
Conflict-of-interest statement: All authors declare that they have no competing interests.
Data sharing statement: No additional data are available.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Kai Duan, Doctor, MMed, Chief Physician, Department of General Practice, Zhengzhou First People’s Hospital, No. 56 Dongdajie Street, Zhengzhou 450000, Henan Province, China. medicalworkers@126.com
Received: August 17, 2022
Peer-review started: August 17, 2022
First decision: December 12, 2022
Revised: January 5, 2023
Accepted: February 15, 2023
Article in press: February 15, 2023
Published online: March 15, 2023
Core Tip

Core Tip: In clinical studies, miR-124 is highly expressed in the serum of patients with diabetes and in pancreatic islet β-cells. In this study, the role and mechanism of miR-124 in diabetes was explored. miR-124 was highly expressed in the diabetic mice, suggesting that the miR-124 was involved in the pathological process of diabetes. In high glucose-induced Min6 cells, miR-124 regulated the insulin secretion, proliferation and apoptosis of islet β-cells by targeting enhancer of zeste homolog 2 (EZH2), indicating that miR-124 was involved in the pathological process of diabetes by targeting EZH2, which might provide a new idea and target for the diagnosis and treatment of diabetes.